Vault-13

FCPM III SERVICES B.V.

NAARDEN, P7 · CIK 2013410 · 13F filing filed 2024-08-08

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$678.1m reported value -4.1% vs Q1 2024
7positions
100.0%in top 10
1 new 0 added 0 reduced 0 sold out vs Q1 2024

This report includes the holdings of 2 other managers that share the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 DYNE THERAPEUTICS INC COM DYN DYN 7,845,364 $276.9m40.83% 40.83% UnchangedShares held: Q3 2023 —, Q4 2023 6.1m, Q1 2024 7.8m, Q2 2024 7.8m
2 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES NAMS NAMS 11,831,461 $227.3m33.52% 33.52% UnchangedShares held: Q3 2023 —, Q4 2023 11.8m, Q1 2024 11.8m, Q2 2024 11.8m
3 ENGENE HOLDINGS INC COM COM 8,677,951 $81.8m12.07% 12.07% UnchangedShares held: Q3 2023 —, Q4 2023 8.7m, Q1 2024 8.7m, Q2 2024 8.7m
4 REPLIMUNE GROUP INC COM REPL REPL 4,866,449 $43.8m6.46% 6.46% UnchangedShares held: Q3 2023 —, Q4 2023 4.9m, Q1 2024 4.9m, Q2 2024 4.9m
5 BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC BCYC 2,122,892 $43.0m6.34% 6.34% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 2.1m
6 ENGENE HOLDINGS INC *W EXP 10/31/202 *W EXP 10/31/202 2,878,148 $3.4m0.51% 0.51% UnchangedShares held: Q3 2023 —, Q4 2023 3.9m, Q1 2024 2.9m, Q2 2024 2.9m
7 ACHILLES THERAPEUTICS PLC SPONSORED ADS SPONSORED ADS 2,390,050 $1.9m0.29% 0.29% UnchangedShares held: Q3 2023 —, Q4 2023 2.4m, Q1 2024 2.4m, Q2 2024 2.4m